Keywords: cvt, enters, pivotal, studies, cvt-510, cv, therapeutics

CVT enters pivotal studies with CVT-510

Article | 18 May 2000

Print This

CV Therapeutics says that it has completed the first part of its PhaseII clinical program for its selective A1 adenosine ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in